Michael KammÃ¼ller

List of Publications by Year
in descending order

41 papers	759 citations	471371 17 h-index	526166 27 g-index
43 all docs	43 docs citations	43 times ranked	799 citing authors

#	Article	IF	Citations
1	Therapeutic antibody glycosylation impacts antigen recognition and immunogenicity. Immunology, 2022, 166, 380-407.	2.0	6
2	Extracellular Matrix-Induced GM-CSF and Hypoxia Promote Immune Control of Mycobacterium tuberculosis in Human In Vitro Granulomas. Frontiers in Immunology, 2021, 12, 727508.	2.2	3
3	Alternative Complement Pathway Inhibition Abrogates Pneumococcal Opsonophagocytosis in Vaccine-NaÃ¯ve, but Not in Vaccinated Individuals. Frontiers in Immunology, 2021, 12, 732146.	2.2	14
4	Alternative Complement Pathway Inhibition Does Not Abrogate Meningococcal Killing by Serum of Vaccinated Individuals. Frontiers in Immunology, 2021, 12, 747594.	2.2	17
5	TNF-Î± antagonists differentially induce TGF-Î²1-dependent resuscitation of dormant-like Mycobacterium tuberculosis. PLoS Pathogens, 2020, 16, e1008312.	2.1	25
6	The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases. Frontiers in Immunology, 2020, 11, 472.	2.2	11
7	Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice. PLoS Pathogens, 2020, 16, e1008477.	2.1	22
8	Generating Three-dimensional Human Granulomas in vitro to Study Mycobacterium tuberculosis-Host Interaction. Bio-protocol, 2020, 10, e3820.	0.2	0
9	Title is missing!. , 2020, 16, e1008312.		0
10	Title is missing!. , 2020, 16, e1008312.		0
11	Title is missing!. , 2020, 16, e1008312.		0
12	Title is missing!. , 2020, 16, e1008312.		0
13	Inhibition of ILâ€17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections. Clinical and Translational Immunology, 2017, 6, e152.	1.7	67
14	New Approaches to Investigate Drug-Induced Hypersensitivity. Chemical Research in Toxicology, 2017, 30, 239-259.	1.7	18
15	T-cell assays confirm immunogenicity of tungsten-induced erythropoietin aggregates associated with pure red cell aplasia. Blood Advances, 2017, 1, 367-379.	2.5	27
16	FRI0025â€...No Reactivation of Dormant Mycobacterium Tuberculosis in Human in Vitro Granuloma Model after anti-IL-17A Treatment, in Contrast To anti-TNFÎ± Treatment. Annals of the Rheumatic Diseases, 2016, 75, 434.2-434.	0.5	3
17	Minipigs in Translational Immunosafety Sciences. Toxicologic Pathology, 2016, 44, 315-324.	0.9	18
18	Controlled Mycobacterium tuberculosis infection in mice under treatment with anti-IL-17A or IL-17F antibodies, in contrast to TNFÎ± neutralization. Scientific Reports, 2016, 6, 36923.	1.6	34

#	Article	IF	Citations
19	Antibody blockade of IL-17 family cytokines in immunity to acute murine oral mucosal candidiasis. Journal of Leukocyte Biology, 2016, 99, 1153-1164.	1.5	52
20	279. Cytokine, 2013, 63, 309.	1.4	0
21	Regulation of Allergic Responses to Chemicals and Drugs: Possible Roles of Epigenetic Mechanisms. Toxicological Sciences, 2012, 130, 60-69.	1.4	12
22	Investigative safety science as a competitive advantage for Pharma. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 1071-1082.	1.5	24
23	Extrapolation of Experimental Safety Data to Humans: The Interleukin-6 Case. Clinical Immunology and Immunopathology, 1997, 83, 15-17.	2.1	10
24	Recombinant human interleukin-6: safety issues of a pleiotropic growth factor. Toxicology, 1995, 105, 91-107.	2.0	25
25	Pathology considerations for, and subsequent risk assessment of, chemicals identified as immunosuppressive in routine toxicology. Food and Chemical Toxicology, 1995, 33, 239-243.	1.8	38
26	Long-term treatment with 5,5-diphenylhydantoin reduces lymphadenopathy and anti-ssDNA autoantibodies in C57BL/6-lpr/lpr mice. International Journal of Immunopharmacology, 1994, 16, 261-268.	1.1	6
27	The identification of chemicals with sensitizing or immunosuppressive properties in routine toxicology. Food and Chemical Toxicology, 1994, 32, 289-296.	1.8	21
28	Long-term interleukin-6 administration stimulates sustained thrombopoiesis and acute-phase protein synthesis in a small primate-- the marmoset. Blood, 1994, 83, 2093-2102.	0.6	15
29	Cataractogenic Effects in Rats Following Chronic Administration of SDZ ICT 322, a Selective 5-HT3 Antagonist. Fundamental and Applied Toxicology, 1993, 21, 393-401.	1.9	5
30	Pathology induced by Interleukin-6. Toxicology Letters, 1992, 64-65, 311-319.	0.4	14
31	VÎ² repertoire in rats and implications for endogenous superantigens. European Journal of Immunology, 1992, 22, 641-645.	1.6	28
32	Urinary biopterin levels in mice during graft-versus-host reactions and during exposure to 5,5-diphenylhydantoin. International Journal of Immunopharmacology, 1991, 13, 463-473.	1.1	2
33	Kinetics and morphology of chemically induced popliteal lymph node reactions compared with antigen-, mitogen-, and graft-versus-host-reaction-induced responses. Vigiliae Christianae, 1989, 58, 279-287.	0.1	21
34	Popliteal lymph node reactions in mice induced by the drug zimeldine. International Journal of Immunopharmacology, 1989, 11, 693-702.	1.1	25
35	The popliteal lymph node assay in mice to screen for the immune disregulating potential of chemicals â€" A preliminary study. International Journal of Immunopharmacology, 1989, 11, 293-300.	1.1	80
36	Spanish toxic oil syndrome: An isothiocyanate-derived compound cannot be substantiated as a causative agent. Food and Chemical Toxicology, 1989, 27, 205-206.	1.8	5

#	Article	IF	Citations
37	Structural requirements for hydantoins and 2-thiohydantoins to induce lymphoproliferative popliteal lym phnode reactions in the mouse. International Journal of Immunopharmacology, 1988, 10, 997-1010.	1.1	30
38	1-phenyl-5-vinyl-2-imidazolidinethione, a proposed causative agent of Spanish toxic oil syndrome: Synthesis, and identification in one of a group of case-associated oil samples. Food and Chemical Toxicology, 1988, 26, 119-127.	1.8	16
39	Chemical-induced autoimmune reactions and spanish toxic oil syndrome. Focus on hydantoins and related compounds. Journal of Toxicology: Clinical Toxicology, 1988, 26, 157-174.	1.5	20
40	SPANISH TOXIC OIL SYNDROME IS A CHEMICALLY INDUCED GVHD-LIKE EPIDEMIC. Lancet, The, 1984, 323, 1174-1175.	6.3	29
41	SPANISH TOXIC OIL SYNDROME AND CHEMICALLY INDUCED GRAFT-VERSUS-HOST-LIKE REACTIONS. Lancet, The, 1984, 324, 805-806.	6.3	15